2010 to 2023 Saw Increase in GLP-1 RA, SGLT2 Inhibitor Use in Type 1 Diabetes
Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.